With the start of pivotal Phase III clinical trials for eprotirome looming, Karo Bio AB has secured SEK530 million (US$79.7 million) to fund the research, by raising SEK300 million in a forthcoming rights issue that is fully guaranteed and another SEK230 million in an equity-based credit facility. (BioWorld International) Read More
